Kohjin Bio
Basic Information
- Stock Code
- 177A
- Industry
- Chemicals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Saitama Prefecture
- Establishment Year
- April 1981
- Listing Year
- April 2024
- Official Website
- https://kohjin-bio.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- JSH, Linical, Transgenic Group, Shin Nippon Science, DNA Chip Research, H.U. Group Holdings, Falco Holdings, BML, Outlook, Nalnet, Human Metabolome Technologies, PhoenixBio
Overview
Kohjin Bio is a bio and pharmaceutical-related company founded in 1981, trusted by medical research institutions at home and abroad for its advanced technologies in manufacturing media for regenerative medicine and cell processing services.
Current Situation
Kohjin Bio is expanding its business in the regenerative medicine field following its listing in 2024, providing high-quality cell culture products through in-house media manufacturing. Its main customers are research institutions and pharmaceutical companies, and it is also developing products for infectious disease testing. To differentiate itself from competitors, it is actively investing in expanding powdered media and strengthening cell processing technologies. It has completed fundraising through a third-party allotment of new shares, and is advancing further expansion of its product lineup and reinforcement of its R&D structure. It has garnered attention in Nikkei News and featured a president interview, heightening market expectations. In the future, it plans overseas expansion of high-performance media and is working on building sustainable manufacturing processes. In the medium to long term, it focuses on technological innovations supporting the foundation of regenerative medicine and aims to expand its share in the cell processing field.
Trivia
Interesting Facts
- Established in 1981 as a pioneer in media manufacturing
- Successfully raised funds via third-party allotment immediately after listing
- Top-class domestic share in powdered media technology
- Highly rated in infectious disease testing reagent development
- Numerous joint development projects with research institutions
- Cell processing services highly evaluated in the industry for precision
- Broad customer base in bio and pharmaceutical fields
- Contributing to expansion of domestic regenerative medicine market
- Owns factories specialized in quality control for medical supplies
- President strengthening influence in the industry
- Responded to increased demand for infectious disease testing during COVID-19
- Continuous advancement of media manufacturing technology since founding
- Technology provision and local contributions in Saitama Prefecture
- Ongoing expansion of domestic share in powdered media for biopharma
- Focus on nurturing young talent in R&D department
Hidden Connections
- Close joint research relationships with major customer research institutions
- Cell processing technology related to domestic regenerative medicine approval projects
- Cooperation in strengthening local government testing systems in infectious disease field
- Technological strength holding many patents in bio-pharma field
- Advancing next-generation media development through industry-academia collaboration with local universities
- Listing funds utilized for modernizing production equipment and strengthening R&D
- Limited collaboration areas with some competitors for mutual complementarity
- Strengthening ties with companies outsourcing medical reagent and testing kit manufacturing
Future Outlook
Growth Drivers
- Rapid expansion of regenerative medicine market
- Increasing demand for high-performance media
- Growing demand for infectious disease testing
- Growth in cell processing service market
- Medical deregulation and technological innovation
- Expansion of distribution channels overseas
- International recognition of high-quality manufacturing technology
- R&D reinforcement using listing funds
- Application of AI and digital technology to manufacturing
- Promotion of new technology development through industry-academia-government collaboration
- Strengthening environmentally considerate product lines
- Expansion of custom-made products
Strategic Goals
- Achieve 30% share in domestic and international regenerative medicine media
- Enter international markets with infectious disease testing reagents
- Reach annual sales of approx. ¥10 billion
- Establish sustainable manufacturing system
- Become industry-leading cell processing outsourcing company
- Build advanced quality control system using AI
- Strengthen global partnerships
- Acquire technology patents and maintain competitive edge
- Aggressively enter new business areas
- Enhance contributions to local communities
Business Segments
Regenerative Medicine Related Products
- Overview
- Provides high-quality media and cell processing services for regenerative medicine, supporting R&D.
- Competitiveness
- Integrated support from media development to cell processing
- Customers
-
- Pharmaceutical companies
- Medical institutions
- Research institutes
- Biotechnology companies
- University labs
- Cell therapy ventures
- Clinical research organizations
- Government research institutions
- Products
-
- Powdered media
- Liquid media
- Supplements
- Cell processing services
- Quality control reagents
- Sterile pack media
Infectious Disease Testing Reagents and Equipment
- Overview
- Division supplying rapid and accurate reagents for infectious disease testing.
- Competitiveness
- High-precision reagent development for rapid testing
- Customers
-
- Clinical testing centers
- Medical institutions
- Public health agencies
- Testing reagent distributors
- Research institutions
- Pharmaceutical companies
- Products
-
- Rapid diagnostic kits
- Infectious disease testing reagents
- Standard solutions
- Quality control products
Cell Culture Technology Outsourcing
- Overview
- Provides specialized cell culture processing services according to customer requirements.
- Competitiveness
- High-quality, customizable cell processing technology
- Customers
-
- Bio companies
- Research institutions
- Pharmaceutical companies
- University labs
- Clinical trial institutions
- Products
-
- Cell culturing processing
- Cell expansion services
- Quality testing outsourcing
Research Reagent Supply
- Overview
- Business segment providing a wide range of reagents for R&D.
- Competitiveness
- System to quickly meet researchers' needs
- Customers
-
- University labs
- Corporate research institutes
- National research institutions
- Products
-
- Media additives
- Cell growth factors
- Analytical reagents
Medical Supplies and Consumables
- Overview
- Stable supply of consumables and equipment for medical sites.
- Competitiveness
- High-quality control system and rapid delivery
- Customers
-
- Hospitals
- Clinics
- Testing facilities
- Pharmaceutical companies
- Products
-
- Sterile packaged products
- Cell culture supplies
- Testing consumables
Competitive Advantage
Strengths
- In-house high-quality media technology
- Integrated provision of cell processing services
- Strong relationships with research institutions and pharmaceutical companies
- Specialized technology in regenerative medicine
- Rapid product development and market response
- Expertise in infectious disease testing
- Enhanced fundraising through listing
- Broad supply to domestic and international clinical research institutions
- Diverse media product lineup
- High-quality control system
- Cell culture optimization know-how
- Strict regulatory compliance
- Custom responses matching customer needs
- Introduction of sustainable manufacturing processes
- Specialized sales and support system
Competitive Advantages
- Seamless provision from media manufacturing to cell processing
- Secured first-mover advantage with expanded powdered media for biopharma in Japan
- High-precision product development in infectious disease testing reagents
- Strengthened R&D and production capacity with listing fundraising
- Comprehensive solutions for broad customer base
- High trust from medical sites through specialized quality control
- Advanced cell processing technology compared to competitors
- Technological innovation through joint development with research institutions
- Rapid product development system adapted to market needs
- Sales strength leveraging domestic and international networks
- Superior compliance system for regulations
- Improved logistics and supply chain efficiency
- Expanded distribution channels through cooperation with specialty distributors
- Business focused on segmented B2B markets
- Leading in sustainable bioproduct manufacturing
Threats
- Risk of stricter regulations in regenerative medicine market
- Market share loss due to competitors' technological innovations
- Instability in fundraising environment
- Rising raw material prices
- Intensifying competition in overseas markets
- Risk of patent infringement in cell culture technology
- Demand fluctuations with infectious disease outbreaks
- Risk of delays in legal compliance for quality control
- Development stagnation due to talent acquisition difficulties
- Profit instability from exchange rate fluctuations
- Aging manufacturing equipment and high renewal costs
- Product obsolescence from changing technology trends
Innovations
2024: Major Expansion of Powdered Media
- Overview
- Expanded lineup of powdered media for biopharma, improving manufacturing efficiency.
- Impact
- 30% increase in production capacity and expanded sales opportunities.
2023: Advancement of Cell Processing Technology
- Overview
- Renewed quality control system for cell processing services, enabling advanced processing.
- Impact
- 15% increase in orders received.
2022: Enhanced Sensitivity of Infectious Disease Testing Reagents
- Overview
- Succeeded in improving sensitivity of rapid infectious disease diagnostic kits, strengthening market competitiveness.
- Impact
- 20% increase in product adoption rate.
2021: Introduction of In-House Media Quality Control System
- Overview
- Introduced AI-utilizing quality control system in manufacturing processes.
- Impact
- 40% reduction in defect rate, enhanced product stability.
2020: Development of New Media Formulas
- Overview
- Successfully developed new media formulas specialized for regenerative medicine.
- Impact
- Enabled market launch of new products.
Sustainability
- Energy-saving initiatives in manufacturing processes
- Improved waste recycling rate
- Adoption of low-environmental-impact packaging materials
- Thorough sustainable resource procurement
- Implementation of in-house environmental awareness programs
- Cooperation in local environmental protection activities
- Workplace environment improvements considering employee health and safety
- Ensuring legal compliance and transparency in environmental reporting
- Introduction of proper bio-waste processing processes
- Enhanced environmental evaluation of regenerative medicine technologies
- Continuous monitoring of energy usage
- CO2 reduction through green logistics promotion